161 related articles for article (PubMed ID: 37230162)
1. Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients.
Machet T; Quémeneur T; Ledoult E; Mesbah R; Lebas C; Hachulla E; Pokeerbux MR
Joint Bone Spine; 2023 Sep; 90(5):105591. PubMed ID: 37230162
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
[TBL] [Abstract][Full Text] [Related]
5. Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.
Gérard M; de Boysson H; Morello R; Martin-Silva N; Leroux AC; Dumont A; Maigné G; Boutemy J; Khoy K; Mariotte D; Lobbedez T; Aouba A; Deshayes S
Scand J Rheumatol; 2023 Mar; 52(2):161-173. PubMed ID: 35048797
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
7. Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation.
Miyazaki Y; Nakayamada S; Kubo S; Ishikawa Y; Yoshikawa M; Sakata K; Iwata S; Miyagawa I; Nakano K; Tanaka Y
Arthritis Res Ther; 2020 Jun; 22(1):141. PubMed ID: 32539843
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
9. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
10. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
12. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Springer JM; Funk RS
J Rheumatol; 2021 Nov; 48(11):1718-1724. PubMed ID: 34334366
[TBL] [Abstract][Full Text] [Related]
14. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
15. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
16. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
19. Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study.
Mendel A; Behlouli H; de Moura CS; Vinet É; Curtis JR; Bernatsky S
Arthritis Res Ther; 2023 Jul; 25(1):133. PubMed ID: 37516897
[TBL] [Abstract][Full Text] [Related]
20. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
Morel P; Karras A; Porcher R; Belenfant X; Audard V; Rafat C; Hanouna G; Beaudreuil S; Vilain C; Hummel A; Terrier B; Pillebout E; Groh M; Jouenne R; Dhote R; Fain O; Ponsoye M; Noel N; Limal N; Puéchal X; Le Jeunne C; Guillevin L; Mouthon L; Régent A
Rheumatology (Oxford); 2022 Oct; 61(10):4056-4064. PubMed ID: 35108368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
